Codexis (CDXS) to Release Earnings on Thursday

Codexis (NASDAQ:CDXS) is anticipated to release its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Codexis to post earnings of ($0.15) per share and revenue of $18.5150 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Codexis (NASDAQ:CDXS) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $15.33 million for the quarter, compared to analyst estimates of $14.18 million. Codexis had a negative net margin of 113.67% and a negative return on equity of 105.83%. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Trading Down 7.2%

CDXS opened at $2.56 on Thursday. The firm’s fifty day moving average is $2.60 and its two-hundred day moving average is $2.54. The company has a debt-to-equity ratio of 0.71, a quick ratio of 5.70 and a current ratio of 5.82. The firm has a market cap of $231.09 million, a PE ratio of -3.08 and a beta of 2.50. Codexis has a twelve month low of $1.90 and a twelve month high of $6.08.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Codexis in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Codexis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Codexis currently has a consensus rating of “Hold” and an average price target of $11.00.

Institutional Trading of Codexis

Institutional investors have recently bought and sold shares of the business. State of Wyoming bought a new stake in shares of Codexis in the second quarter valued at approximately $25,000. Osaic Holdings Inc. boosted its stake in shares of Codexis by 1,922.9% in the second quarter. Osaic Holdings Inc. now owns 20,634 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 19,614 shares during the period. XTX Topco Ltd bought a new stake in shares of Codexis in the second quarter valued at approximately $116,000. Invesco Ltd. boosted its stake in shares of Codexis by 42.4% in the second quarter. Invesco Ltd. now owns 96,078 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 28,631 shares during the period. Finally, Bridgeway Capital Management LLC boosted its stake in shares of Codexis by 6.7% in the second quarter. Bridgeway Capital Management LLC now owns 100,908 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 6,300 shares during the period. Institutional investors own 78.54% of the company’s stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.